AF Spotlight: Using NOACs Safely: Overview, Dosing, Transitioning, and Using a Patient-centered Approach

Title:

AF Spotlight: Using NOACs Safely: Overview, Dosing, Transitioning, and Using a Patient-centered Approach

Topic: Cardiology
Relevant Terms: Atrial Fibrillation, NOACs, stroke prevention, bleeding
Primary Audience: Cardiologists, Clinical Cardiologists, Interventional Cardiologists, EPs, Internal Medicine/Primary Care Physicians, Endocrinologists, NPs/PAs, Fellows, Nurses, and other healthcare providers involved in the care of patients with atrial fibrillation
Launch Date: 05-Jan-16
Credits: 1.5 AMA PRA Category 1 Credits
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: AF Spotlight: Using NOACs Safely

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Assess the clinical experience and potential of NOACs to manage thromboembolic risk associated with AF
  2. Apply the AHA/ACC/HRS and EHRA guidelines for anticoagulant management of patients with AF
  3. Describe ways to initiate NOAC therapy, switch between agents, transition between agents, and take into account dosing considerations
  4. Use patient-centered approaches for the management of stroke prevention in patients with AF

    Faculty

    A. John Camm, MD
    Professor of Clinical Cardiology
    St. George's University of London and Imperial College
    London, UK
    Christopher B. Granger, MD
    Professor of Medicine
    Duke University
    Director, Cardiac Intensive Care Unit
    Duke University Medical Center
    Durham, NC
    Christian T. Ruff, MD, MPH
    Investigator, TIMI Study Group
    Assistant Professor, Harvard Medical School
    Associate Physician, Cardiovascular Medicine Division
    Brigham and Women's Hospital
    Boston, MA
    Jeffrey Weitz, MD
    Professor of Medicine & Biochemistry and Biomedical Sciences
    McMaster University
    Executive Director
    Thrombosis & Atherosclerosis Research Institute
    Hamilton, ON, Canada
    Estimated time to complete activity: 1.5 hours.
     
    This activity is jointly provided by Postgraduate Institute for Medicine (www.pimed.com) and Medtelligence.
     
    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.
     
    Physician Continuing Medical Education
    Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Medtelligence. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
     
    Credit Designation
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    A. John Camm, MD: Consulting Fees: Mitsubishi, Laguna, Bayer, BIOTRONIK, Richmond Pharmacology, Boehringer Ingelheim, Daiichi, Menarini, Novartis, St. Jude Medical, Bristol-Myers Squibb, Medtronic, Servier, Boston Scientific, and Eli Lilly and Company; Speakers Bureau: Pfizer; Data Safety Monitoring Board: BIOTRONIK and St. Jude Medical; Organizational (non-commercial): European Heart Rhythm Association.
     
    Christopher B. Granger, MD: Research Grants: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic Foundation, Pfizer, Sanofi-Aventis, Takeda, The Medicines Company, AstraZeneca, Daiichi Sankyo, Janssen Pharmaceuticals, and Armetheon; Consulting Fees (including CME): Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Hoffman-La Roche, Pfizer, Sanofi-Aventis, Takeda, The Medicine Company, AstraZeneca, Janssen Pharmaceuticals, Salix Pharmaceuticals, Gilead, and Medtronic.
     
    Christian T. Ruff, MD, MPH: Consulting Fees: Daiichi Sankyo, Boehringer Ingelheim, Bayer, and Portola.
     
    Jeffrey Weitz, MD: Consulting Fees: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, Portola, Janssen, and Isis Pharmaceuticals.
     
    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
     
    The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Jan Schultz, MSN, RN, CHCP, and Judi Smelker-Mitchek, RN, BSN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
     
    Medtelligence: Ben Caref, PhD; Pamela Clark - No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

    Media
    Internet
     
    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
     
    Method of Participation and Request for Credit
    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
    • Read the learning objectives and faculty disclosures
    • Participate in the activity
    • Complete the post-test and activity evaluation
    Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
     
    For any questions about the accreditation of this activity, please contact PIM at (800) 423-3576 or information@pimed.com.
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6+ for Mac OSX 10.7 and above
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 7.0 or above